Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells
Avtorji:ID Omerzel, Maša (Avtor)
ID Jesenko, Tanja (Avtor)
ID Markelc, Boštjan (Avtor)
ID Cerovšek, Anja (Avtor)
ID Serša, Gregor (Avtor)
ID Čemažar, Maja (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://sciendo.com/article/10.2478/raon-2022-0009
 
.pdf PDF - Predstavitvena datoteka, prenos (1,01 MB)
MD5: 95B8226E6DBEADAF47600F94FC387EB9
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:One of the new treatment options for unresectable locally advanced pancreatic cancer is electro-chemotherapy (ECT), a local ablative therapy that potentiates the entry of chemotherapeutic drugs into the cells, by the application of an electric field to the tumor. Its feasibility and safety were demonstrated in preclinical and clinical studies; however, there is a lack of preclinical studies assessing the actions of different drugs used in ECT, their mechanisms and interactions with other target drugs that are used in clinical practice. Materials and methods. The aim of the study was to determine the cytotoxicity of two chemotherapeutic drugs usually used in ECT (bleomycin and cisplatin) in the BxPC-3 human pancreatic carcinoma cell line and evaluate the interactions of ECT with the targeted drug sunitinib. First, the cytotoxicity of ECT using both chemotherapeutics was determined. In the next part, the interactions of ECT and sunitinib were evaluated through determination of combined cytotoxicity, sunitinib targets and kinetics of cell death.Results. The results demonstrate that ECT is effective in pancreatic cancer cell line, especially when bleomycin is used, with the onset of cell death in the first hours after the treatment, reaching a plateau at 20 hours after the treat-ment. Furthermore, we provide the rationale for combining ECT with bleomycin and the targeted drug sunitinib to potentiate cytotoxicity. The combined treatment of sunitinib and ECT was synergistic for bleomycin only at the high-est used concentration of bleomycin 0.14 μM, whereas with lower doses of bleomycin, this effect was not observed. The interaction of ECT and treatment with sunitinib was confirmed by course of the cell death, also indicating on synergism
Ključne besede:electrochemotherapy, pancreas, sunitinib, pancreatic cancer
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.06.2022
Založnik:Association of Radiology and Oncology
Leto izida:2022
Št. strani:str. 164-172
Številčenje:Vol. 56, no. 2
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19761 Novo okno
UDK:616-006-085
ISSN pri članku:1318-2099
DOI:10.2478/raon-2022-0009 Novo okno
COBISS.SI-ID:105234179 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:24.07.2024
Število ogledov:300
Število prenosov:173
Metapodatki:XML DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:elektrokemoterapija, trebušna slinavka, sunitinib, rak trebušne slinavke


Nazaj